WALTHAM, Mass.--(BUSINESS WIRE)--
NeuroMetrix, Inc. (NURO)
today reported commercial expansion of DPNCheck® in Mexico
following receipt of a purchase order from one of Mexico's six major
government healthcare institutions. With this most recent order, two of
these six major institutions have now adopted DPNCheck for early
detection of diabetic peripheral neuropathy (DPN).
Mexico has one of the highest rates of diabetes in the world with a
prevalence of nearly 10.8% as reported by The Organization for Economic
Co-Operation and Development (OECD). The disease results in 80,000
deaths per year making diabetes the second leading cause of death for
the country. The prevalence of diabetes is projected to increase in the
coming years.
Scienta Farma, S.A.de C.V. is the exclusive distributor of DPNCheck in
Mexico. The most significant market opportunity is within the public
institutions that provide healthcare services to the majority of
Mexico's 120 million citizens. Scienta Farma focuses its marketing and
sales efforts on government contracts with these institutions.
"DPNCheck is ideally suited for rapid screening of DPN in a large
patient population," said Alberto Elias Fernandez, Executive Vice
President of Scienta Farma. "We believe that clinical adoption will
advance the overall management of diabetes in Mexico."
"Mexico is an increasingly significant component of our DPNCheck
business," said Michael MacDonald, NeuroMetrix Senior Vice President of
Commercial Operations. "Scienta Farma is doing a great job in growing
adoption within the critical governmental healthcare sector."
About DPNCheck
DPNCheck is a quantitative nerve conduction test that is used by
physicians and health care professionals to evaluate systemic
neuropathies such as diabetic peripheral neuropathy, or DPN. It is
designed to be used at the point-of-care to objectively detect, stage,
and monitor DPN. The device measures nerve conduction velocity and
response amplitude of the sural nerve, a nerve in the lower leg and
ankle. These parameters are recognized as sensitive and specific
biomarkers of DPN.
About NeuroMetrix
NeuroMetrix is an innovative health-care company that develops wearable
medical technology and point-of-care tests that help patients and
physicians better manage chronic pain, nerve diseases, and sleep
disorders. The company is located in Waltham, Massachusetts and was
founded as a spinoff from the Harvard-MIT Division of Health Sciences
and Technology in 1996. For more information, please visit www.NeuroMetrix.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160713005129/en/
NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
SVP and
Chief Financial Officer
neurometrix.ir@neurometrix.com
Source: NeuroMetrix, Inc.
News Provided by Acquire Media
